The inhibition of NaV1.1, by CBD and CBGA, demonstrated here, suggest that these phytocannabinoids may also be promising therapeutics for patients who carry a GOF recurrent missense variant (p.Thr226Met) in the SCN1A gene, which presents with an extremely severe developmental and early infantile epileptic encephalopathy phenotype (Berecki et al., 2019). Here, SCN1A is linked to early-infantile DEE.